- Record: found
- Abstract: not found
- Article: not found
Primary Mutational Landscape Linked with Pre-Docetaxel Lactate Dehydrogenase Levels Predicts Docetaxel Response in Metastatic Castrate-Resistant Prostate Cancer
Kenneth Hiew ,
Claire A. Hart ,
Adnan Ali ,
Tony Elliott ,
Vijay Ramani ,
Vijay Sangar ,
Maurice Lau ,
Satish Maddineni ,
Mick Brown ,
Noel Clarke
April 2018
April 2018
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Docetaxel chemotherapy is a standard of care for metastatic castrate-resistant prostate
cancer (mCRPC): 40-50% of patients achieve a biochemical response. However, there
is a lack of response predictive biomarkers.